Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome

Abstract Background and aims Dietary fructose may play a role in the pathogenesis of metabolic syndrome (MetS). In a recently published study of obese children with MetS, we showed that isocaloric fructose restriction reduced fasting triglyceride (TG) and LDL-cholesterol (LDL-C). In these ancillary...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 2016-10, Vol.253, p.171-177
Hauptverfasser: Gugliucci, Alejandro, Lustig, Robert H, Caccavello, Russell, Erkin-Cakmak, Ayca, Noworolski, Susan M, Tai, Viva W, Wen, Michael J, Mulligan, Kathleen, Schwarz, Jean-Marc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background and aims Dietary fructose may play a role in the pathogenesis of metabolic syndrome (MetS). In a recently published study of obese children with MetS, we showed that isocaloric fructose restriction reduced fasting triglyceride (TG) and LDL-cholesterol (LDL-C). In these ancillary analyses, we tested the hypothesis that these effects were also accompanied by improved quantitative and qualitative changes in LDL and HDL subclasses and their apolipoproteins; as well as change in VLDL, particularly apoC-III. Methods Obese children with MetS (n = 37) consumed a diet that matched self-reported macronutrient composition for nine days, with the exception that dietary fructose was reduced from 11.7 ± 4.0% to 3.8 ± 0.5% of daily calories and substituted with glucose (in starch). Participants underwent fasting biochemical analyses on Days 0 and 10. HDL and LDL subclasses were analyzed using the Lipoprint HDL and LDL subfraction analysis systems from Quantimetrix. Results Significant reductions in apoB (78 ± 24 vs . 66 ± 24 mg/dl) apoC-III (8.7 ± 3.5 vs . 6.5 ± 2.6 mg/dl) and apoE (4.6 ± 2.3 vs . 3.6 ± 1.1 mg/dl), all p  
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2016.06.048